DelMar Pharmaceuticals Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083
DelMar now holds seven allowed United States patents and eight international patents with more than 100 additional patent filings from thirteen patent families representing patent claims covering VAL-083 to 2036
VANCOUVER, British Columbia and MENLO PARK, Calif., Dec. 14, 2016 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for United States Patent Application Serial No. 13/933,844 entitled, "Improved Analytical Methods for Analyzing and Determining Impurities in Dianhydrogalactitol."
The patent has also been granted in Australia and is being prosecuted in other international jurisdictions as part of more than 100 patent filings from thirteen patent families representing claims covering VAL-083 until 2036.
"This patent provides DelMar with ownership of essential manufacturing controls required under good manufacturing practice (GMP) guidelines," said Jeffrey Bacha, chairman and CEO of DelMar Pharmaceuticals. "This is an important component of our strategy to establish a strong international patent portfolio as the foundation to support the global development of VAL-083 in multiple cancer indications."
DelMar is preparing to advance VAL-083 into a pivotal Phase III clinical trial in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
The Company has also recently presented data and outlined plans for expansion of VAL-083 into new indications, including newly diagnosed GBM, ovarian and lung cancer. DelMar's most recent abstract entitled "Assessment of Dianhydrogalactitol (VAL-083) in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer" was presented at the 17th World Congress on Lung Cancer in Vienna, Austria on December 7, 2016.
Further details regarding DelMar's scientific presentations can be found at http://www.delmarpharma.com/scientific-publications.html.
The USPTO issues a Notice of Allowance after it makes a determination that a claimed invention is novel and nonobvious in light of all known technology in existence, and that a patent should be granted from such an application. Based on the timing of this Notice of Allowance, DelMar Pharmaceuticals expects the forthcoming US patent to be issued in early 2017.
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.
For further information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: [email protected] / (604) 629-5989. Connect with the Company on Twitter, LinkedIn, Facebook, and Google+.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.
SOURCE DelMar Pharmaceuticals, Inc.
Share this article